Dakar

Dakar has emerged as a premier life sciences hub in West Africa, distinguished by its leadership in vaccine manufacturing and biotechnology innovation.

The ecosystem is anchored by the world-renowned Institut Pasteur de Dakar (IPD), which remains the only WHO-prequalified producer of the yellow fever vaccine on the continent and is currently scaling production through the MADIBA project.

This state-of-the-art facility in the Diamniadio industrial zone is revolutionizing pharmaceutical supply chains by targeting the production of 300 million doses annually, including mRNA vaccines and diagnostics for neglected tropical diseases.

Beyond manufacturing, Dakar is a center for academic research and genomic surveillance, hosting the WHO Regional Health Emergency Hub to bolster pandemic preparedness across the Sahel.

The city’s healthcare innovation sector is fueled by public-private partnerships that accelerate clinical trials and the development of low-cost medical devices.

Furthermore, Senegal's robust regulatory environment and focus on health sovereignty make it an attractive destination for biopharma investment and global R&D collaborations.

By integrating bioinformatics and digital health solutions, Dakar is effectively bridging the gap between cutting-edge biomedical research and community-level patient care.

Overall, the region represents a critical frontier for emerging markets in the global life sciences industry, combining historical expertise with futuristic infrastructure.